AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
LEG

Leggett & Platt Incorporated Common Stock (LEG) fair value

Consumer Cyclical · Furnishings, Fixtures & Appliances · NYSE · United States
$9.20-1.29%
Market cap $1.3BNext earnings 2026-08-06Updated Oct 18, 2026
Our verdict
Trades 50% below our fair value
Price
$9.20
Model fair valueConfidence: good
$18.50
Model range
$10.10 to $28.30
Fair value $18.50
Price $9.20
4 models fit Leggett & Platt Incorporated Common Stock and they partly agree: 2 of 4 land within 15% of the average. The price is below every model.
Two or more of our models back this value.
Large discount(i)Bronze48
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionLeggett & Platt Incorporated Common Stock (LEG)
Fair value (4 models)
$18.50
ACCE price target
$8.80
Rating
Undervalued
Horizon
12 months
Fair value published on 18 Oct 2026, 15:06 CEST; previously $18.29 since 14 Oct 2026, 00:00 CEST.
ACCE price target published on 12 Oct 2026, 00:00 CEST.
Rating published on 18 Oct 2026, 15:06 CEST.
Price used: $9.20 at the close on 3 Sept 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
50.3% below
+101.1% to fair value
ACCE score
30
out of 100
Analysts
0% buy
4 covering
P/E
5.9x
forward 14.6x
1-year return
-2.4%
Dividend yield
2.15%

Leggett & Platt Incorporated Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Leggett & Platt makes the components that sit inside other people's furniture and mattresses: steel innersprings, wire forms, foam, and mechanisms for reclining chairs and adjustable beds, sold mostly to bedding and furniture manufacturers. Its moat is scale and entrenched supplier relationships rather than brand, and that matters because the business has been shrinking, with revenue down 5.5% and gross margin at 19.1%, so the case rests on whether the cost base is being reset faster than volumes fall. The near-term catalyst is a housing and home-furnishings recovery, which would lift replacement and remodel demand, though nothing in the data shows that turn yet. At a trailing P/E of 5.9 against a forward P/E of 14.6, the market is pricing in earnings that are expected to fall further, not recover, so the low multiple reflects that skepticism. The ROE of 22.6% is flattered by a small equity base and should not be read as evidence of quality on its own. The score of 47/100 and absence from any index argue for a deeper look only if the reader has a view on the furniture cycle and on management's restructuring progress.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
  • severe
    Short interest extremely high
    Short interest stands at 19.2% of the float, a level that signals heavy bearish positioning and can amplify volatility in either direction.
  • high
    Leverage elevated against equity
    Debt/Equity of 1.62 leaves little cushion if revenue keeps shrinking, with revenue down 5.5% YoY and earnings down 12.9% YoY.
  • high
    Revenue and earnings contracting
    Revenue fell 5.5% YoY and earnings fell 12.9% YoY, with a 5-year revenue CAGR of -1.1%, so the business is shrinking over multiple years rather than in one bad quarter.
  • moderate
    ACCE score collapsed
    The ACCE score dropped 19 points over 90 days, from 49 to 30, and the stock trades 4.5% above the ACCE price target of $8.80.

AI research notes

AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-06-30 · prices to Sep 3, 2026
Why it could do well
  • Free cash flow over the last 12 months reached $281M, and the dividend yield is 2.2%.
  • Latest quarterly earnings beat expectations, with earnings per share of 0.39 against 0.29 expected, a surprise of +34.5%.
Why it could disappoint
  • Revenue fell 5.5% year over year, and the five-year average annual revenue growth is -1.1%.
  • Return on invested capital is 7.2%, and debt to equity sits at 1.62, which leaves little margin for error.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where LEG's valuation models land
Price
$9.20
Model fair value
$18.50
Model range
$10.10 to $28.30
Fair value $18.50
Price $9.20
The price is below the whole model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bearish0% buy · 4 covering analysts
● Strong buy 0● Buy 0● Hold 4● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+0.0%
1 month
-11.9%
3 months
-8.1%
6 months
-13.5%
YTD
-16.4%
1 year
-2.4%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
18 Oct 2026, 15:06 CESTRatingUndervaluedfirst publication$9.20
18 Oct 2026, 15:06 CESTFair value$18.50$18.29$9.20
14 Oct 2026, 00:00 CESTFair value$18.29$15.06$9.20
12 Oct 2026, 00:00 CESTACCE price target$8.80first publication$9.20
6 Oct 2026, 00:00 CESTFair value$15.06$15.25$9.20
15 Sept 2026, 00:00 CESTFair value$15.25$15.49$9.20
30 Aug 2026, 00:00 CESTFair value$15.49$16.19$9.20
22 Aug 2026, 00:00 CESTFair value$16.19$17.32$9.41
20 Aug 2026, 00:00 CESTFair value$17.32$17.75$9.54
7 Aug 2026, 00:00 CESTFair value$17.75$18.02$9.87

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full LEG page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth7Value-Quality52Momentum-Total30
Valuation
Trailing P/E
5.9x
Forward P/E
14.6x
PEG
2.96
P/B
1.16x
EV / Revenue
0.6x
Book value/sh
$7.92
Enterprise value
$2.4B
Profitability
ROE
22.6%
FCF yield
22.36%
ROIC
7.2%
Health and risk
Debt / equity
1.62
Dividend yield
2.15%
Beta
0.75

Price

+0.9% · 1Y

Ask anything about LEG

Answered from Leggett & Platt Incorporated Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 67% of peers
low 0.0x5.9xhigh 15.1x
ROEbetter than 83% of peers
low -6%23%high 23%
Div yieldbetter than 50% of peers
low 0.0%2.1%high 10.8%

Peers

Prices Sep 3, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
LEG Leggett & Platt Incorporated Common Stock$9.20$1850% below5.9x22.6%5230
LZB La-Z-Boy Incorporated Common Stock$30.40$3819% below15.1x8.1%5152
1999.HK Man Wah Holdings LimitedHK$2.22HK$553% below4.9x13.2%6441
MLKN MillerKnoll Inc. Common Stock$21.68$22At fair value14.0x7.3%4766
MBC MasterBrand Inc. Common Stock$7.35$622% above--5.8%3031
WHR Whirlpool Corporation Common Stock$28.80$8064% below9.2x5.9%2532
TILE Interface Inc. Common Stock$36.51$2078% above14.2x23.2%8180

Sector report card

Where LEG ranks against its sector peers on each metric.

Computing percentiles…
  • GlobeNewswire•Oct 15, 2026
    Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
  • Business Wire•Oct 15, 2026
    LegalZoom and USAA Join Forces to Deliver Legal Solutions for America’s Service Members and Their Families
  • GlobeNewswire•Oct 1, 2026
    Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
20 more press releases · full archive on Investor+.INVESTOR
40 filings
August 2026
Aug 27
Form 4Insider transactionPeriod 2026-08-26
View on SEC →
Aug 27
Form 4Insider transactionPeriod 2026-08-26
View on SEC →
Aug 27
Form 4Insider transactionPeriod 2026-08-26
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR